By combining a diagnosis of RBD with other clinical non-motor signs of neurodegenerative alpha-synucleinopathies, such as olfactory dysfunction and neuroimaging of impaired dopamine transporter ligand binding (i.e. 123I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)tropane single photon emission computed tomography, FP-CIT-SPECT), one can define a subgroup of patients with a high probability of conversion to motor Parkinsonism within a few years [17, 22]. Here, SLC6A3 is linked to synucleinopathy.